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We also appreciate
suggestions from the
readers for
improvements that
can make the
journal even better.
We learn much more
by listening than by
talking.We are always interested in getting feedback on how the journal is doing and how it can be
improved, and apart from the occasional irate musings from a disgruntled rejected author,
people seem almost too complimentary. Therefore, it is a bit refreshing when we can have open
conversations with those I will call “stakeholders” in the journal. These, of course, are not just
editors but board members, authors, and frequent reviewers. As many of you know, we have board
meetings of the JACC family of journals at the major international scientiﬁc sessions, i.e., ACC,
AHA, ESC meetings, and now, for JACC: Cardiovascular Interventions, we have just concluded
a meeting to listen to some of the stakeholders in this journal. We are obviously also interested in
the reaction to interventional cardiovascular content of the parent JACC as well. The opportunity
for this discussion was the EuroPCR meeting in Paris, where about 50 of our colleagues who could
break away from other commitments engaged in a lively discussion with Tony DeMaria and
myself. Mirroring the EuroPCR, which is heavily attended by cardiologists from around the world,
the United States being an unfortunate exception, we heard opinions from our colleagues from
Europe, the Middle East, Asia, and South America, as well as the United States. This was
a welcomed mix as over 70% of submissions to JACC: Cardiovascular Interventions continue to
come from outside the United States. This truly is an international journal. A number of issues
were discussed, and I will mention the ones that some of you may want to reﬂect on, as will we.
All those in attendance were pleased to have their papers published in a journal with a high
impact factor, such as JACC: Cardiovascular Interventions; however, some are disappointed with
rejection of their high-quality studies. We agreed, but with an acceptance rate of just over 10%, our
page limitation requires prioritizing and excluding many papers that we would like to publish.
Suggestions to address this issue include online-only publication of certain articles. The group was
polled to see how many would accept the idea of publishing their paper online only. I was surprised
with how many would be willing for this to happen. However, since our most recent survey shows
that a signiﬁcant majority of our readers still read the print version, they may not see the online
material. Nonetheless, this is food for thought.
Another approach to increase the number of articles per issue and to shorten the papers. It is
interesting to see how many submissions are close to the 4,500-word limit given in the Instructions
for Authors. It sometimes seems that authors feel that if they must use the entire word limit
amount. We have not been diligent enough as editors in urging a shorter version after acceptance.
When papers are shortened as recommended they are almost always improved. Perhaps we should
take advice from Benjamin Franklin who said on submitting a paper on electricity to the Royal
Society in London, “I have already made this paper too long for which I must crave pardon, not
having now time to make it shorter.”
Another concern that was expressed was the competition for journal space between long-term
follow-up articles on clinical trials with intermediate results already reported versus innovative but
largely hypothesis-generating studies. One solution that we have begun to suggest for incremental
follow-up of previously published trials is a very short research communication with trial design
and methods referenced with the paper only focusing on the things that changed with the longer-
term follow-up. Often a concise paper is more impactful than a verbose one. For original research,
some methods and tables can be put in online appendices but most felt that the key methods must
remain in the print version so the paper can be completely understood without referring to another
source. I queried the group for opinions about pro/con opinion pieces. The response was almost
unanimous that they did not feel the journal was the place for these debates, but should depend on
well-crafted editorials for selected articles when such comments seemed called for. Some issues
may still call for expression of differing interpretations of the available data.
Finally, the recurring question of whether this is a clinical journal only or one open to early-
phase technology arose. Certainly we intend to do both, although our major responsibility is to
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765provide the readership, mostly clinical, with papers
that have a chance to inﬂuence therapy. That said,
we do want to make sure that the innovative ideas of
our scientists are communicated to the broad
cardiovascular community. With the very large
readership of JACC: Cardiovascular Interventions we
have the opportunity to do this, and we will be
diligent not to let high-quality, innovative research
slip by.
It was a very worthwhile interaction, and we will
continue to hold these types of sessions at venues
attended by large numbers of our board members,authors, and frequent reviewers. We also appreciate
suggestions from the readers for improvements that
can make the journal even better. We learn much
more by listening than by talkingAddress correspondence to:
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